Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2011-07-19
2011-07-19
Allen, Marianne P (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S350000, C530S363000, C514S015200, C514S010800
Reexamination Certificate
active
07982018
ABSTRACT:
The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically urocortin and urocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides and derivatives to serum components, preferably serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group, which is covalently attached to a modified peptide or derivative, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide or derivative to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention preferably exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and preferably exhibit increased biological activity compared to the unconjugated peptides. The present invention also provides methods for the treatment and prevention of a disease or disorder comprising the administration of one or more of the compounds or conjugates of the invention to a subject in need of such treatment or prevention.
REFERENCES:
patent: 3719667 (1973-03-01), Gutowski
patent: 3840556 (1974-10-01), Kukolja
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5686511 (1997-11-01), Bobo
patent: 5876969 (1999-03-01), Fleer et al.
patent: 5998367 (1999-12-01), Gaeta et al.
patent: 6063761 (2000-05-01), Jones et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 6818611 (2004-11-01), Altman
patent: 6838274 (2005-01-01), Vale et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 7307148 (2007-12-01), Bousquet-Gagnon et al.
patent: 2002/0082409 (2002-06-01), Hsu
patent: 2003/0165807 (2003-09-01), Isfort et al.
patent: 2004/0106589 (2004-06-01), Webb et al.
patent: 2006/0099571 (2006-05-01), Altman
patent: 2009/0175821 (2009-07-01), Bridon et al.
patent: 1234586 (2002-08-01), None
patent: 92/01476 (1992-02-01), None
patent: 95/10302 (1995-04-01), None
patent: 96/29342 (1996-09-01), None
patent: 97/00063 (1997-01-01), None
patent: 99/07404 (1999-02-01), None
patent: 99/24076 (1999-05-01), None
patent: 99/25727 (1999-05-01), None
patent: 99/25728 (1999-05-01), None
patent: 00/012346 (2000-03-01), None
patent: 00/69900 (2000-11-01), None
patent: 01/17568 (2001-03-01), None
patent: 02/34934 (2002-05-01), None
patent: WO-2005/012346 (2005-02-01), None
patent: 2005/099768 (2005-10-01), None
patent: 2005/103087 (2005-11-01), None
patent: 2007/049941 (2007-05-01), None
patent: 2007/071068 (2007-06-01), None
Asakawa et al., Gastroenterology 1999, 116:1287-1292 (1999).
Campfield, Smith et al., Science 269:546-549 (1995).
Dodsworth et al,. Biotechnol. Appl. Biochem. 24:171-176 (1996).
GenBank Database, Accession No. AC005903 (Jan. 9, 2003).
GenBank Database, Accession No. AF331517 (Mar. 6, 2001).
GenBank Database, Accession No. BE622276 (Oct. 20, 2000).
Halaas, Gajiwala et al., Science 269:543-6 (1995).
Hashimoto et al., Peptides 25:1711-1721 (2004).
Hsu and Hsueh, “Human stresscopin and stresscopin-related peptide are selective ligands fOI the type 2 corticotropin-releasing hormone receptor,” Nature Medicine 7: 605-611 (May 2001).
Liaw et al., Endocrinology 137:72-74, (1996).
Lewis, K. et al, “Identificiation of urocortin III, an additional member of the corticotropinreleasing factor (CRF) family with high affinity for the CRF2 receptor,” Proc. Natl. Acad. Sci. USA 98(13): 7570-7575 (Jun. 19, 2001).
Lovenberg et al., PNAS USA 92:836-840 (1995).
Pelleymounter, Cullen et al., Science 269:540-543 (1995).
Perrin et al., PNAS USA 92:2969-2973 (1995).
Perrin et al., Endocrinology 133:3058-3061 (1993).
Reyes, T.M. et al, “Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors,” Proc. Natl' Acad. Sci. USA 98(5): 2843-2848 (Feb. 27, 2001).
Stehle et al., Anticancer Drugs 8:677-685 (1997).
Takahashi et al. Peptides 25:1723-1731 (2004).
Isfort et al., “Modifications of the Human Urocortin 2 Peptide That Improve Pharmacological Properties”, Peptides, 27:1806-1813, 2006.
Jetté, L. et al. (Jul. 2005, e-published Apr. 7, 2005). “Human Growth Hormone-Releasing Factor (hGRF)1-19Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog,”Endocrinology, downloaded from <http://www.endo.endojournals.org,> last visited Feb. 5, 2009, 146(7):3052-3058.
Estradier Jean-Philippe
Thibaudeau Karen
Ulich Thomas R.
Allen Marianne P
Conjuchem, LLC
Morrison & Foerster / LLP
LandOfFree
Modified corticotropin releasing factor peptides and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified corticotropin releasing factor peptides and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified corticotropin releasing factor peptides and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635150